Effect of a single IV administration of L-propionylcarnitine on myocardial microcirculation assessed by coronary flow velocity reserve measurement in patients with systemic sclerosis: a pilot study.

[1]  P. Siotto,et al.  Absence of epicardial coronary stenosis in patients with systemic sclerosis with severe impairment of coronary flow reserve , 2006, Annals of the rheumatic diseases.

[2]  O. Vignaux,et al.  Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis , 2005, Annals of the rheumatic diseases.

[3]  W. C. Hülsmann,et al.  Carnitine requirement of vascular endothelial and smooth muscle cells in imminent ischemia , 1992, Molecular and Cellular Biochemistry.

[4]  J. Ioannidis,et al.  Mortality in systemic sclerosis: an international meta-analysis of individual patient data. , 2005, The American journal of medicine.

[5]  Eugenio Picano,et al.  Informed consent and communication of risk from radiological and nuclear medicine examinations: how to escape from a communication inferno , 2004, BMJ : British Medical Journal.

[6]  J. Tanne.  US accrediting agency tightens rules for continuing medical education , 2004, BMJ : British Medical Journal.

[7]  L. Ferrari,et al.  Uptake and release of carnitine by vascular endothelium in culture; effects of protons and oxygen free radicals , 1995, Molecular and Cellular Biochemistry.

[8]  F. Schena,et al.  Short-term hemodynamic effects of intravenous propionyl-L-carnitine in anesthetized dogs , 1991, Cardiovascular Drugs and Therapy.

[9]  V. Hinsbergh,et al.  Effect of propionyl-L-carnitine on human endothelial cells , 2004, Cardiovascular Drugs and Therapy.

[10]  P. Colonna,et al.  Detection of early impairment of coronary flow reserve in patients with systemic sclerosis , 2003 .

[11]  D. Stepp,et al.  Regulation of shear stress in the canine coronary microcirculation. , 1999, Circulation.

[12]  S. Iliceto,et al.  Validation of a new noninvasive method (contrast-enhanced transthoracic second harmonic echo Doppler) for the evaluation of coronary flow reserve: comparison with intracoronary Doppler flow wire. , 1999, Journal of the American College of Cardiology.

[13]  C Caiati,et al.  Contrast-enhanced transthoracic second harmonic echo Doppler with adenosine: a noninvasive, rapid and effective method for coronary flow reserve assessment. , 1999, Journal of the American College of Cardiology.

[14]  C Caiati,et al.  New noninvasive method for coronary flow reserve assessment: contrast-enhanced transthoracic second harmonic echo Doppler. , 1999, Circulation.

[15]  L. Packer,et al.  Antiradical effects in L-propionyl carnitine protection of the heart against ischemia-reperfusion injury: the possible role of iron chelation. , 1992, Archives of biochemistry and biophysics.

[16]  N. Suzuki,et al.  Significance of plasma endothelin-1 levels in patients with systemic sclerosis. , 1992, The Journal of rheumatology.

[17]  A. Bertelli,et al.  Inhibition of histamine release and pressure increase induced by endothelin (ET-1) in isolated rat kidneys treated with propionyl carnitine. , 1992, Drugs under experimental and clinical research.

[18]  P. Lachenbruch,et al.  Cardiac score. A semiquantitative measure of cardiac involvement that improves prediction of prognosis in systemic sclerosis. , 2010, Arthritis and rheumatism.

[19]  L. Packer,et al.  Free radical scavenging is involved in the protective effect of L-propionyl-carnitine against ischemia-reperfusion injury of the heart. , 1991, Archives of biochemistry and biophysics.

[20]  B. Amor,et al.  Reduced coronary flow and resistance reserve in primary scleroderma myocardial disease. , 1986, American heart journal.

[21]  B. Amor,et al.  Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. , 1986, The New England journal of medicine.

[22]  J. Hoffman.  Maximal coronary flow and the concept of coronary vascular reserve. , 1984, Circulation.

[23]  T. Medsger,et al.  Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. , 1984, The New England journal of medicine.

[24]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[25]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[26]  G. Hutchins,et al.  Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: a clinicopathologic study of 9 patients with progressive systemic sclerosis. , 1978, American heart journal.

[27]  G. Hutchins,et al.  Myocardial Lesions of Progressive Systemic Sclerosis: A Cause of Cardiac Dysfunction , 1976, Circulation.

[28]  S. Zoneraich,et al.  Scleroderma heart disease with slow flow velocity in coronary arteries. , 1975, Chest.

[29]  T. N. James,et al.  De Subitaneis Mortibus: VIII. Coronary Arteries and Conduction System in Scleroderma Heart Disease , 1974, Circulation.

[30]  T. K. Marshall,et al.  De Subitaneis Mortibus: V. Occluded A‐V Node Artery , 1974, Circulation.

[31]  A. Masi,et al.  Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. , 1971, Annals of internal medicine.